Compare Cipla with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GSK PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GSK PHARMA CIPLA/
GSK PHARMA
 
P/E (TTM) x 23.3 53.4 43.6% View Chart
P/BV x 2.4 11.2 21.2% View Chart
Dividend Yield % 0.7 1.4 48.0%  

Financials

 CIPLA   GSK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
GSK PHARMA
Mar-19
CIPLA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6783,595 18.9%   
Low Rs4841,253 38.6%   
Sales per share (Unadj.) Rs198.2184.7 107.3%  
Earnings per share (Unadj.) Rs18.526.3 70.5%  
Cash flow per share (Unadj.) Rs35.029.2 120.0%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.50.8 62.6%  
Book value per share (Unadj.) Rs186.3126.3 147.5%  
Shares outstanding (eoy) m805.70169.40 475.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.913.1 22.3%   
Avg P/E ratio x31.492.2 34.0%  
P/CF ratio (eoy) x16.683.1 20.0%  
Price / Book Value ratio x3.119.2 16.2%  
Dividend payout %16.276.1 21.3%   
Avg Mkt Cap Rs m468,031410,626 114.0%   
No. of employees `00022.65.0 456.5%   
Total wages/salary Rs m28,5655,372 531.7%   
Avg. sales/employee Rs Th7,053.16,306.7 111.8%   
Avg. wages/employee Rs Th1,261.51,083.1 116.5%   
Avg. net profit/employee Rs Th659.1898.0 73.4%   
INCOME DATA
Net Sales Rs m159,71031,281 510.6%  
Other income Rs m4,7661,023 465.8%   
Total revenues Rs m164,47532,304 509.1%   
Gross profit Rs m30,9736,009 515.5%  
Depreciation Rs m13,263486 2,729.0%   
Interest Rs m1,6846 28,071.7%   
Profit before tax Rs m20,7916,540 317.9%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m5,6952,373 240.0%   
Profit after tax Rs m14,9244,454 335.1%  
Gross profit margin %19.419.2 101.0%  
Effective tax rate %27.436.3 75.5%   
Net profit margin %9.314.2 65.6%  
BALANCE SHEET DATA
Current assets Rs m124,26620,061 619.4%   
Current liabilities Rs m37,71514,543 259.3%   
Net working cap to sales %54.217.6 307.2%  
Current ratio x3.31.4 238.9%  
Inventory Days Days9157 159.6%  
Debtors Days Days9514 674.7%  
Net fixed assets Rs m105,19014,343 733.4%   
Share capital Rs m1,6111,694 95.1%   
"Free" reserves Rs m148,51119,704 753.7%   
Net worth Rs m150,12321,398 701.6%   
Long term debt Rs m38,3012 1,915,035.0%   
Total assets Rs m239,63339,113 612.7%  
Interest coverage x13.31,091.0 1.2%   
Debt to equity ratio x0.30 272,966.4%  
Sales to assets ratio x0.70.8 83.3%   
Return on assets %6.911.4 60.8%  
Return on equity %9.920.8 47.8%  
Return on capital %11.831.9 37.1%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,410534 10,750.8%   
Fx outflow Rs m19,0417,091 268.5%   
Net fx Rs m38,368-6,557 -585.1%   
CASH FLOW
From Operations Rs m16,9113,994 423.4%  
From Investments Rs m-16,687-1,433 1,164.1%  
From Financial Activity Rs m-3,487-3,584 97.3%  
Net Cashflow Rs m-3,451-1,023 337.3%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 50.7 41.0%  
Indian inst/Mut Fund % 12.2 10.2 119.6%  
FIIs % 23.7 23.8 99.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 15.4 170.1%  
Shareholders   161,166 102,036 158.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PROCTER & GAMBLE HEALTH  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Gains 300 Points; Hero MotoCorp & Maruti Suzuki Top Gainers(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Signs of easing trade tension between the US and China provided some respite to investors globally.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 15, 2019 02:07 PM

TRACK CIPLA

CIPLA - SANOFI INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS